Deliver Your News to the World

Third Time’s A Charm For Nuvo Research (TSE:NRI), (OTC:NRIFF)


StocksHaven Investments news portal takes a closer look at Nuvo Research Inc. (TSE:NRI), (PINK:NRIFF) which hopes its novel osteoarthritis treatment Pennsaid will be approved by the FDA on August/5/09.

Nuvo Research Inc. has been red hot this past month and is expected to continue. StocksHaven Investments has identified Nuvo Research as its top candidate for undervalued biotech pre-PDUFA. With a current PPS below $1.00 CAD, and their product Pennsaid, a new and innovative treatment for osteoarthritis having expected net sales of $200-400 million in the U.S., Nuvo Research (TSE:NRI) could see extensive gains leading prior to their expected FDA decision on Aug/5/09 as investors gain confidence in the company once again.

The company’s stock has been sizzling, in fact it has been so hot, it is up 120% from May/19/09 - June/16/09.

The full special report appears at

Disclosure: Short-Term Position


About StocksHaven Investments

StocksHaven Investments can be found at It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, investment dictionary, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers PR relations and contracting services.

For more financial and investment news, visit

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 fda pennsaid approval
 pdufa pennsaid nuvo
 nuvo research inc

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.